Boulder, Colo., USA - September 3, 2012, Boulder, Colo., USA - Array BioPharma Inc., a biopharmaceutical company, announced that Francis Bullock and Kevin Koch will not to stand for reelection to the board, and that David L. Snitman intends to resign from the board of directors, effective October 24, 2012.
Article continues below
Dr. Bullock has served as a member of the Board of Directors since May 1998. Dr. Bullock is currently an independent consultant. From 2002 to 2003, Dr. Bullock was a Senior Advisor for the Strategic Decisions Group, a management consulting firm. From 1993 to 2002, Dr. Bullock was a Senior Consultant at Arthur D. Little, Inc., concentrating on pharmaceutical and biotechnology R&D, as well as the fine chemicals and agricultural chemicals industries.
From 1981 to 1993, Dr. Bullock served as the Senior Vice President, Research Operations at Schering Plough Research Institute. Dr. Bullock has served on the Board of Directors of publicly-traded ARCA biopharma, Inc. and GTC Biotherapeutics and Atherex, a privately-held company. As part of his responsibilities as an Array Board member, Dr. Bullock serves on the Board's Audit, Compensation and Corporate Governance Committees.
Dr. Bullock received a B.S. in pharmacy from the Massachusetts College of Pharmacy, an A.M. in organic chemistry from Harvard University and a Ph.D. in Organic Chemistry from Harvard University.
Dr. Koch is a Co-Founder of Array and has served as President, Chief Scientific Officer and a member of the board of directors since May 1998. Prior to forming Array, Dr. Koch was an Associate Director of Medicinal Chemistry and Project Leader for the Protease Inhibitor and New Leads Project Teams for Amgen, Inc. from 1995 to 1998. From 1988 until 1995, Dr. Koch held various positions with Pfizer Central Research, including Senior Research Investigator, Project Coordinator for the Cellular Migration and Immunology Project Teams.
From 1998 until 2003, Dr. Koch was an elected board member of the Inflammation Research Association. Dr. Koch received a B.S. in chemistry and biochemistry from the State University of New York at Stony Brook, and a Ph.D. in synthetic organic chemistry from the University of Rochester.
Dr. Snitman is a Co-Founder of Array and has served as Chief Operating Officer, Vice President of Business Development, and a member of the Board of Directors since May 1998. Prior to forming Array, Dr. Snitman held various positions with Amgen Inc. since 1981, including Associate Director, New Products and Technology and Manager of Amgen's Boulder research facility.
Dr. Snitman received a B.S. in chemistry from Northeastern University and obtained a Ph.D. in the synthesis of natural products from the University of Colorado. He was an NIH Postdoctoral Fellow at the Massachusetts Institute of Technology. ■